EP-104
Knee Osteoarthritis Pain
Key Facts
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals' mission is to develop differentiated therapies for pain and inflammation through its proprietary platform for localized, extended-release drug delivery. Its key achievement is the completion of a Phase 2 trial for EP-104 in knee osteoarthritis, advancing it toward pivotal studies. The company's strategy is to leverage its drug-device combination platform to create products with superior therapeutic profiles in targeted anatomical sites, aiming to capture value in large markets like osteoarthritis with high unmet need for durable, non-systemic treatments.
View full company profileAbout Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals' mission is to develop differentiated therapies for pain and inflammation through its proprietary platform for localized, extended-release drug delivery. Its key achievement is the completion of a Phase 2 trial for EP-104 in knee osteoarthritis, advancing it toward pivotal studies. The company's strategy is to leverage its drug-device combination platform to create products with superior therapeutic profiles in targeted anatomical sites, aiming to capture value in large markets like osteoarthritis with high unmet need for durable, non-systemic treatments.
View full company profileTherapeutic Areas
Other Knee Osteoarthritis Pain Drugs
| Drug | Company | Phase |
|---|---|---|
| MM-II | Moebius Medical | Phase 3 |